Dual inhibition of MEK and mTOR effectively suppressed KRAS mutant- and FBXL6-driven HCC, and this finding may provide a potential treatment strategy for this cohort of HCC patients with high FBXL6 expression and high RAS/ERK activation. The gene discussed is MAP2K7; the disease is hepatocellular carcinoma.